Predictors of Carotid Occlusion Intolerance during Proximal Protected Carotid Artery Stenting

Original title: Predictors of Carotid Occlusion Intolerance During Proximal Protected Carotid Artery Stenting. Reference: Giuseppe Giugliano et al. J Am Coll Cardiol Intv 2014, Epub ahead of print.

Proximal endovascular occlusion devices (PEO) have been proved particularly effective and safe for proximal protected carotid stenting procedures. However, endovascular occlusion can expose the ipsilateral hemisphere to hypoperfusion and produce transient neurological symptoms.

Between March 2010 and 2012, 605 consecutive patients undergoing proximal protected carotid stenting in one center were included in this trial (Mo.Ma, Medtronic Inc., Santa Rosa, California). In order to identify independent predictors of carotid occlusion intolerance, multivariate logistic regression model was developed that included all clinical, angiographic and procedural characteristics of patients.

Compared to the asymptomatic subjects, those who presented intolerance had a lower occlusion pressure (42.3 ± 12.7 vs. 61.9 ± 15.4 mmHg; p< 0.001).

The most powerful independent predictor of proximal protection intolerance was occlusion pressure, with best cutoff being ≤40 mmHg (sensitivity 68.5%, specificity 93.3%). The best clinical predictor was the presence of collateral internal carotid artery occlusion (OR 3.1, IC 95% 1.5 a 6.2). 

Conclusion

Transient neurological symptoms can occur in one third of patients undergoing proximal protected carotid stenting. Contralateral Carotid occlusion and a ≤ 40 mmHg occlusion pressure are the best predictors.

Editorial Comment

Proximal occlusion intolerance has not been associated to peri procedural events and symptoms completely resolve within the first 20 minutes after flow restoration. Most of the times symptoms start after stenting (during post dilation or aspiration) therefore it is possible to finish procedure under protection. Only 1% of cases started with symptoms immediately after balloon inflation, in these cases the balloon may be deflated and the system may be used as a sheath guide filtered catheterization.

SOLACI

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...